Global Veterinary Infectious Diseases Therapeutics Market Size By Type (Antibiotics, Antiviral), By Application (Swine, Chicken), By Region, And Segment Forecasts, 2023 to 2032

The Global Veterinary Infectious Diseases Therapeutics Market was valued at USD 4.3 billion in 2023 and is expected to reach USD 7.8 billion by 2031, growing at a CAGR of 7.5% during the forecast period from 2023 to 2031. The growth is driven by the increasing prevalence of zoonotic and livestock-related infectious diseases, rising pet ownership, expanding veterinary healthcare infrastructure, and growing investments in animal health R&D. Therapeutics addressing bacterial, viral, and parasitic infections in animals have become pivotal as global demand for food safety, public health, and companion animal care increases.

Drivers:

1. Growing Incidence of Zoonotic and Livestock Infectious Diseases

A surge in outbreaks such as bovine tuberculosis, foot-and-mouth disease, avian influenza, and canine distemper is intensifying the need for effective veterinary therapeutics.

2. Increasing Pet Ownership and Awareness

The expanding pet population, especially in urban centers, combined with heightened awareness of animal health, is accelerating the adoption of advanced treatments and preventive care.

3. Technological Advancements in Veterinary Medicine

Progress in biologics, including vaccines and monoclonal antibodies, along with digital diagnostic tools, is enhancing disease detection and therapeutic efficacy.

Restraints:

1. High Cost of Veterinary Therapeutics

Premium therapeutics, especially in advanced formulations or novel delivery systems, can be cost-prohibitive, particularly for small-scale livestock farmers.

2. Regulatory and Supply Chain Constraints

Complex regulatory frameworks and disruptions in the supply chain for veterinary pharmaceuticals can impact market availability and adoption rates.

Opportunity:

1. Expansion in Emerging Markets

Developing countries in Asia-Pacific and Latin America are witnessing robust growth in veterinary services and livestock production, offering untapped opportunities.

2. Demand for Preventive and Alternative Therapies

The rise of preventive healthcare, including vaccines and immune-boosting formulations, and interest in herbal or natural therapeutics is reshaping the market landscape.

Market by System Type Insights:

Based on therapeutic type, Antibacterial Agents held the dominant market share in 2023, owing to their widespread use in both companion animals and livestock. However, Vaccines are projected to witness the fastest growth, driven by government immunization programs and advancements in recombinant and vector-based vaccines.

Market by End-use Insights:

By end-use, the Livestock segment accounted for the largest share in 2023, particularly in bovine and swine therapeutics. The Companion Animals segment, especially dogs and cats, is anticipated to grow rapidly due to increased pet humanization and higher per-animal spending in developed economies.

Market by Regional Insights:

North America dominated the market in 2023, benefiting from a mature veterinary pharmaceutical sector, supportive reimbursement models, and advanced diagnostic capabilities. However, the Asia-Pacific region is forecasted to exhibit the fastest CAGR due to growing livestock production, rising disposable incomes, and expanding access to veterinary services in countries such as India and China.

Competitive Scenario:

Leading players in the global veterinary infectious diseases therapeutics market include Zoetis Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Merck & Co., Inc., Ceva Santé Animale, Virbac, Dechra Pharmaceuticals, Bayer Animal Health, and Vetoquinol S.A. These companies are focusing on product innovation, strategic alliances, and regional expansion.

Recent Developments:

In 2023, Zoetis Inc. launched a broad-spectrum antimicrobial product aimed at treating respiratory infections in cattle.

In 2024, Elanco entered a strategic partnership with a leading Indian veterinary diagnostics firm to develop localized infectious disease therapies.

In 2025, Ceva Santé Animale introduced a novel viral vaccine for poultry in Southeast Asia, targeting Newcastle disease and avian influenza.

Scope of Work – Global Veterinary Infectious Diseases Therapeutics Market

FAQs:

1) What is the current market size of the Global Veterinary Infectious Diseases Therapeutics Market?

The market size was USD 4.3 billion in 2023.

2) What is the major growth driver of the Global Veterinary Infectious Diseases Therapeutics Market?

The major growth driver is the rising incidence of infectious diseases among livestock and pets.

3) Which is the largest region during the forecast period in the Global Veterinary Infectious Diseases Therapeutics Market?

North America held the largest market share in 2023, but Asia-Pacific is projected to grow at the highest rate.

4) Which segment accounted for the largest market share in the Global Veterinary Infectious Diseases Therapeutics Market?

The Livestock segment held the largest market share in 2023.

5) Who are the key market players in the Global Veterinary Infectious Diseases Therapeutics Market?

Key players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, Ceva Santé Animale, and Virbac.